ReviewMolecules (Basel, Switzerland)2020
Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis-A Short Bridge between Two Distant Illnesses.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 40 citations in OpenAlex.
- Protective Immunity Induced by DNA Vaccines Encoding TgGRA47 and TgGRA72 AgainstTransboundary and emerging diseases · 2026Article
- In Vitro Inhibitory Activity of Corilagin and Punicalagin AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Crystal structure of 1-[(4-chloro-phen-yl)di-phenylyl-meth-yl]-3-(tri-fluoro-meth-yl)-1Acta crystallographica. Section E, Crystallographic communications · 2025Article
- Novel drug candidates targetingFrontiers in pharmacology · 2025Article
- In Vitro Evaluation of Anti-Parasitic Activities of Quinolone-Coumarin Hybrids Derived from Fluoroquinolones and Novobiocin Against Toxoplasma gondii.Acta parasitologica · 2024Article
- Anti-Food science & nutrition · 2024Article
- Identification of fungal natural products with potent inhibition inMicrobiology spectrum · 2024Article
- Quercetin inhibits Toxoplasma gondii tachyzoite proliferation and acts synergically with azithromycin.Parasites & vectors · 2023Article
- Anti-Toxoplasma gondii activity of Trametes versicolor (Turkey tail) mushroom extract.Scientific reports · 2023Article
- Toxoplasma metabolic flexibility in different growth conditions.Trends in parasitology · 2022Review
- Inhibition ofFrontiers in cellular and infection microbiology · 2022Article
- Impact of Plant-Based Foods and Nutraceuticals onFrontiers in nutrition · 2022Review
- Toxoplasmosis: Current and Emerging Parasite Druggable Targets.Microorganisms · 2021Review
- Assessment of the Activity of Decoquinate and Its Quinoline-Molecules (Basel, Switzerland) · 2021Article
- Promising Drug Targets and Compounds with Anti-Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Toxoplasmosis is an infectious disease with paramount impact worldwide, affecting many vulnerable populations and representing a significant matter of concern. Current therapies used against toxoplasmosis are based essentially on old chemotypes, which fail in providing a definitive cure for the disease, placing the most sensitive populations at risk for irreversible damage in vital organs, culminating in death in the most serious cases. Antimalarial drugs have been shown to possess key features for drug repurposing, finding application in the treatment of other parasite-borne illnesses, including toxoplasmosis. Antimalarials provide the most effective therapeutic solutions against toxoplasmosis and make up for the majority of currently available antitoxoplasmic drugs. Additionally, other antiplasmodial drugs have been scrutinized and many promising candidates have emanated in recent developments. Available data demonstrate that it is worthwhile to explore the activity of classical and most recent antimalarial chemotypes, such as quinolines, endoperoxides, pyrazolo[1,5-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.